share_log

Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline

Investors One-year Losses Continue as Northeast Pharmaceutical Group (SZSE:000597) Dips a Further 6.9% This Week, Earnings Continue to Decline

東北製藥(SZSE:000597)本週進一步下跌6.9%,投資者連續一年虧損,收益持續下降。
Simply Wall St ·  06/06 21:06

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. For example, the Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) share price is down 22% in the last year. That contrasts poorly with the market decline of 10%. However, the longer term returns haven't been so bad, with the stock down 17% in the last three years. Even worse, it's down 19% in about a month, which isn't fun at all.

passively investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk underperformance. For example, Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) 股票在過去一年中下跌了22%。這與市場下跌10%形成了鮮明的對比。然而,長期回報表現並不差,股票過去三年下跌了17%。更糟糕的是,一個月內下跌了19%,這一點都不好玩。

Given the past week has been tough on shareholders, let's investigate the fundamentals and see what we can learn.

考慮到過去一週對股東來說是艱難的,讓我們調查一下基本面並看看我們能學到什麼。

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的話順便說一下,“船隻將環遊世界,但支持地球平面學會的人將大有可爲。 在市場上,價格和價值之間將繼續存在巨大的差異...”通過比較EPS和股價變化,我們可以了解到投資者對公司的態度隨時間的變化程度。

Unfortunately Northeast Pharmaceutical Group reported an EPS drop of 2.6% for the last year. The share price decline of 22% is actually more than the EPS drop. So it seems the market was too confident about the business, a year ago.

不幸的是,東北製藥報告了去年的每股收益下降了2.6%。股票下跌了22%,實際上比每股收益下跌更多。因此,似乎市場對公司業務前景過於樂觀了一年。

The image below shows how EPS has tracked over time (if you click on the image you can see greater detail).

下圖顯示了EPS隨時間的變化情況(如果您單擊該圖像,則可以查看更多詳細信息)。

earnings-per-share-growth
SZSE:000597 Earnings Per Share Growth June 7th 2024
SZSE:000597每股收益增長爲2024年6月7日

This free interactive report on Northeast Pharmaceutical Group's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further.

如果您想進一步調查股票,東北製藥的收益,營業收入和現金流免費互動報告是一個很好的起點。

A Different Perspective

不同的觀點

While the broader market lost about 10% in the twelve months, Northeast Pharmaceutical Group shareholders did even worse, losing 20% (even including dividends). Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 3% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Northeast Pharmaceutical Group has 2 warning signs we think you should be aware of.

儘管整個市場在過去的12個月裏大約下跌了10%,但東北製藥的股東情況更糟,損失了20%(甚至包括分紅派息)。儘管如此,在下跌的市場中,一些股票被超賣是不可避免的。關鍵是將目光放在基本發展上。不幸的是,去年的表現是一個糟糕的趨勢的總結,股東們在過去的五年裏每年面臨着總體虧損3%。一般來說,長期股價走弱可能是一個不好的信號,但持有反其道而行之的投資者可能希望研究股票以尋求逆轉。儘管考慮市場狀況對股票價格會有不同的影響是值得的,但還有其他更重要的因素。例如,承擔風險——東北製藥有兩個警告信號,我們認爲您應該知道。

Of course Northeast Pharmaceutical Group may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

當然,東北製藥可能不是最好的購買股票。因此,您可能希望查看這些強勁增長股票的免費收藏。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論